GSK reports Q2 results on July 28 against an awkward backdrop: the stock is down 1.4% on the week while close pharma peers have moved sharply higher, leaving GSK as the relative laggard heading into the print.
The peer divergence is the week's sharpest tension. BMY gained nearly 7% over the same period, MRK added 4.5%, and even AZN — GSK's most direct LSE comparison — closed up 1%. NOVN and UCB both rose more than 2%. GSK's 1.4% weekly decline stands out in that context. The month-long trend reinforces the message: the stock is down roughly 1.7% over the past month while broad pharma has broadly outperformed. A recent note on momentum flagged the 91-day relative strength swinging from +18 to -114, and the 50-day moving average is now just 1% above the 200-day — the narrowest gap in several months.
The lending market tells a very different story, and it's worth naming the contrast directly. Short interest is negligible. Availability is essentially unlimited — there are over 2.3 billion shares available to borrow, and the availability metric has been capped at its maximum reading throughout the past month. Borrowing costs run at just 0.54%, and have actually eased about 11% over the past 30 days. The ORTEX short score is 35.2, drifting lower from 35.8 earlier in the week, and sits in the 63rd percentile on the short score rank — not a name where shorts are pressing. Any bearish thesis on GSK this week is being expressed through price action, not through the borrow market.
The analyst picture is modestly constructive but thin on recent catalysts. The consensus is a buy, with six buy-rated analysts logged as of mid-July. No price target has been filed in the past 14 days, so the Street's formal view is unchanged into earnings. On valuation, the P/E has drifted lower — down 0.35 turns over the past month to around 10x — while EV/EBITDA has compressed roughly 0.16 turns to 7.4x. Those are not alarming moves, but they reflect a stock that has been quietly de-rated even as earnings expectations have held. The dividend score ranks in the 94th percentile, reflecting GSK's historically strong yield credentials, though the dividend data in the system is stale and not actionable for current yield calculations.
Institutional ownership is stable and well-distributed. BlackRock holds 10.3% of shares, the largest single position. FMR (Fidelity) added around 20.6 million shares in its most recent filing period — the largest reported addition among the top holders — while Dodge & Cox trimmed modestly. Amundi added roughly 12.4 million shares. The overall picture is one of passive and semi-active institutional anchoring, with no obvious large-scale exit. Insider activity has been quiet since late April, when an independent director bought £105,000 worth of shares at around 1963p — a modest conviction signal at a price above the current level of 1893p.
The setup for July 28 is therefore less about whether the borrow market is stressed — it plainly is not — and more about whether the Q2 print and updated guidance can close the performance gap that has opened between GSK and the rest of large-cap pharma over the past month.
See the live data behind this article on ORTEX.
Open GSK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
